Apellis Pharmaceuticals, Inc. Logo

Apellis Pharmaceuticals, Inc.

Biopharmaceutical company developing therapies by targeting the complement cascade.

APLS | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
100 FIFTH AVENUE, 2451 WALTHAM

Description

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2026-01-09 19:48
PRIMARY DOCUMENT
English ZIP 7.6 KB
2026-01-06 22:06
PRIMARY DOCUMENT
English ZIP 6.7 KB
2026-01-05 22:42
PRIMARY DOCUMENT
English ZIP 7.8 KB
2026-01-05 22:39
PRIMARY DOCUMENT
English ZIP 7.3 KB
2026-01-05 22:38
PRIMARY DOCUMENT
English ZIP 7.2 KB
2026-01-05 22:37
PRIMARY DOCUMENT
English ZIP 7.3 KB
2026-01-05 22:36
PRIMARY DOCUMENT
English ZIP 7.2 KB
2026-01-05 22:35
PRIMARY DOCUMENT
English ZIP 7.2 KB
2026-01-05 22:34
PRIMARY DOCUMENT
English ZIP 7.2 KB
2026-01-05 21:06 English ZIP 7.0 KB
2025-12-18 22:06
PRIMARY DOCUMENT
English ZIP 7.1 KB
2025-12-16 16:24 English ZIP 7.2 KB
2025-11-18 16:05
PRIMARY DOCUMENT
English ZIP 7.1 KB
2025-11-17 16:28 English ZIP 7.2 KB
2025-11-14 21:45 English ZIP 11.8 KB

Automate Your Workflow. Get a real-time feed of all Apellis Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Apellis Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Apellis Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AVADEL PHARMACEUTICALS PLC Logo
Biopharmaceutical company developing therapies for sleep disorders, focusing on narcolepsy.
United States of America
AVDL
Avalon GloboCare Corp. Logo
Develops cell-based immunotherapies and provides precision diagnostics and lab services.
United States of America
ALBT
Avidity Biosciences, Inc. Logo
Develops a class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs).
United States of America
RNA
Axogen, Inc. Logo
Develops and commercializes surgical solutions for peripheral nerve repair.
United States of America
AXGN
Axsome Therapeutics, Inc. Logo
A biopharmaceutical company developing therapies for central nervous system disorders.
United States of America
AXSM
AYTU BIOPHARMA, INC Logo
A specialty pharma company developing novel therapeutics for complex CNS diseases.
United States of America
AYTU
Azitra, Inc. Logo
Clinical-stage biopharma company developing microbiome-based therapies for skin diseases.
United States of America
AZTR
Bachem Holding AG Logo
A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.
Switzerland
BANB
Barinthus Biotherapeutics plc. Logo
Clinical-stage biopharma developing immunotherapies that guide T cells to control disease.
United States of America
BRNS
Basilea Pharmaceutica AG Logo
Biopharmaceutical firm developing drugs for severe bacterial and fungal infections.
Switzerland
BSLN

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.